JSPR Jasper Therapeutics, Inc.
Legal ·
Defendants: Jasper and unnamed current and former officers; derivative suits are captioned against Martell and others. A motion to dismiss was set for hearing October 15, and no ruling is reported.
Jasper Therapeutics will pay $0.324 in cash per warrant for up to 12,345,707 warrants, about $4.0 million if all are tendered, and the offer runs until November 6, 2026.
Nasdaq notified Jasper (JSPR) on June 3, 2026 that its voting common stock closed below $1.00 for thirty consecutive business days. The notice has no immediate effect on trading; a reverse stock split is among the options named.
Jasper priced 11,670,707 shares and 675,000 pre-funded warrants, each with a common warrant, at $2.43, for about $30 million before costs. The prospectus also discloses an unresolved trial investigation and a going concern warning.
Jasper's board approved a corporate reorganization on July 8, 2025. The company will focus on briquilimab in chronic urticaria, expects $1.8 million to $2.2 million in severance cash costs, and its chief medical officer is leaving.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $63.1 million | $55.8 million |
| Net income (loss) | -$75.8 million | -$71.3 million |
| Cash from operations | -$77.2 million | -$62.6 million |
| Cash and equivalents | $28.7 million | $71.6 million |
Our latest story on this, dated Jun 9, 2026: "Jasper Therapeutics receives Nasdaq minimum bid price notice, has until November 30, 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 15, 2026: "Jasper Therapeutics faced Oct 15 hearing on motion to dismiss briquilimab class action". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 18, 2025: "Jasper Therapeutics prices $30 million offering of stock and warrants". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 18, 2025: "Jasper Therapeutics prices $30 million offering of stock and warrants". The story links the filing or release it is based on. Read the story.
Jasper Therapeutics, Inc. trades under the ticker JSPR on NASDAQ.
Jasper Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Jasper Therapeutics, Inc. is 1788028. Its filings are on SEC EDGAR.
33,274,561 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Jasper Therapeutics, Inc. under United States.
Our directory classifies Jasper Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Jasper Therapeutics, Inc. is US4718712023.
aibio.space lists Jasper Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Jasper Therapeutics, Inc. reported a net loss of $75.8 million for the fiscal year ended Dec 31, 2025, and used $77.2 million of cash in operations, per its annual report to the SEC.
$63.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Offered to buy back its own securities. SEC Form SC TO-I. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,3.02,5.02,5.03,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a financing. SEC Form 424B5. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,8.01,9.01). Source
Reported a financing. SEC Form S-3. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio